University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Virology Papers

Virology, Nebraska Center for

1-5-2001

Genetic and Biological Variation in Equine Infectious Anemia
Michael Belshan
Creighton University, michaelbelshan@creighton.edu

Prasith Baccum
Iowa State University

J. Lindsay Oaks
Washington State University, Pullman

Brett A. Sponseller
Iowa State University

Sean C. Murphy
Iowa State University
See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/virologypub
Part of the Virology Commons

Belshan, Michael; Baccum, Prasith; Oaks, J. Lindsay; Sponseller, Brett A.; Murphy, Sean C.; Cornette,
James; and Carpenter, Susan, "Genetic and Biological Variation in Equine Infectious Anemia" (2001).
Virology Papers. 150.
https://digitalcommons.unl.edu/virologypub/150

This Article is brought to you for free and open access by the Virology, Nebraska Center for at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an
authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Michael Belshan, Prasith Baccum, J. Lindsay Oaks, Brett A. Sponseller, Sean C. Murphy, James Cornette,
and Susan Carpenter

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
virologypub/150

Published in Virology 279:1 (January 5, 2001), pp. 185–200; doi 10.1006/viro.2000.0696
Copyright © 2001 Academic Press/Elsevier. Used by permission. http://www.sciencedirect.com/science/journal/00426822

Submitted July 10, 2000; revised September 8, 2000; accepted October 3, 2000; published online March 12, 2002.
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Abstract
Genetic and biological variation in the regulatory protein Rev of equine infectious anemia virus (EIAV) were examined throughout a
clinically dynamic disease course of an experimentally infected pony. Following infection with the virulent EIAVWyo, the pony underwent a variable disease course, including an acute fever episode at 12 days postinfection (DPI), multiple recurrent fever episodes until
135 DPI, a prolonged subclinical period, and two late fever episodes. Viral RNA was isolated from the inoculum and sequential sera
samples, and the rev exon 2/gp45 overlapping ORFs were amplified, cloned, and sequenced. Novel variants were found throughout
infection, and genetic analyses indicated that both the Rev and gp45 ORFs were under selective pressure. The Rev variant predominant in the inoculum, R1, remained predominant during the early periods following infection (until 35 DPI); however, R1 was replaced by new predominant variants during the recurrent fever period (67–135 DPI). R1 reemerged as the predominant variant during
the afebrile period, but a new predominant variant, R93, was associated with the late fever episodes. Rev variants predominant during
recurrent febrile and late-febrile periods had significantly higher Rev-mediated nuclear export activity than the variants predominant
during the acute and afebrile periods. Statistical correlation was found between Rev activity and different stages of clinical disease.
Together, these results suggest that genetic and biological variation in rev may be a contributing factor in EIAV disease progression.
Keywords: EIAV, Rev, persistence, quasispecies, variation, evolution

Introduction

of errors produced by reverse transcriptase, is a well-studied mechanism of lentivirus persistence (Hubner et al.,
1992; Ji and Loeb, 1994; Nowak, 1990; Patel and Preston, 1994). The result of the genetic variation is the accumulation of nonidentical, yet related, variants commonly
referred to as a quasispecies (Domingo et al., 1996; Eigen,
1993; Holland et al., 1992). Selection acts on the quasispecies population, and the diversity within the population allows the virus to adapt to changes in selective pressures. The quasispecies nature of EIAV is largely the result
of three regions of hypervariability: the viral long terminal repeat (LTR), the surface envelope (SU), and a region
where the major exon of Rev is completely overlapped
by the transmembrane protein (TM). Variation in SU, resulting from mutations, insertions, or duplications within
the principal neutralization domain or hypervariable region, can alter antigenicity and facilitate evasion of host
immune surveillance (Payne et al., 1984, 1987, 1989;
Kono, 1969, 1972; Salinovich et al., 1986; Perryman et
al., 1988; Montelaro et al., 1990; Issel et al., 1990; Kono
et al., 1973; Zheng et al., 1997). Studies examining the
immune response of EIAV-infected horses indicate that
both cellular and humoral immune responses contrib-

Equine infectious anemia virus (EIAV) possesses common features of the Lentiviridae subfamily of retroviruses,
including a complex genome organization, tropism for cells
of the monocyte/macrophage lineage, and establishment of
a persistent, life-long infection. Many lentivirus infections
are characterized by a slow, chronic disease, but infection
of horses with EIAV can result in an acute, dynamic disease
course characterized by recurring cycles of viremia, fever,
and thrombocytopenia, with a possible development of
anemia (reviewed in Issel and Coggins, 1979). Fever cycles
are typically irregular and may recur for up to 1 year, despite the onset of a neutralizing- antibody response. Horses
which survive these initial clinical episodes become lifelong, inapparent carriers of the virus. The variable nature
of clinical disease and the fact that most infected horses are
able to control virus replication and remain life-long inapparent carriers make EIAV infection an excellent model for
studies of virus and host factors which contribute to lentivirus persistence and pathogenesis.
Virus persistence over a life-long infection is dependent
on both host and viral factors. Genetic variation, the result
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ute to suppression of virus replication during inapparent
stages of infection (Salinovich et al., 1986; Hammond et
al., 1997). No subset of the immune response, however,
was ever previously shown to specifically correlate with
control of virus replication during long-term persistence
(Hammond et al., 1997).
Lentiviruses have evolved complex mechanisms to regulate viral gene expression at the transcriptional and posttranscriptional levels. Variation in regulatory elements
such as the LTR and Rev may alter the level of virus gene
expression and, subsequently, viral replication (Carpenter
et al., 1991; Alexandersen and Carpenter, 1991; Maury et
al., 1997). We and others described genetic variation in
the second exon of the EIAV regulatory protein Rev (Alexandersen and Carpenter, 1991; Belshan et al., 1998; Leroux et al., 1997), but the biological significance of Rev
variation in vivo has not yet been explored. Rev functions
to facilitate the nuclear export of the incompletely spliced
viral RNAs during the late phase of virus replication.
These viral RNAs encode the structural proteins and serve
as progeny RNA molecules. Rev-dependent RNA export
pathways have been described for numerous lentiviruses
(reviewed in Cullen, 1992; Hope, 1997), and the human
immunodeficiency virus type 1 (HIV-1) Rev-mediated export pathway is the best characterized. HIV-1 Rev binds a
structure in the viral pre-mRNA, called the Rev-responsive
element (RRE) (Zapp and Green, 1989), multimerizes (Olsen et al., 1990), then utilizes the CRM1 nuclear export
pathway to redirect movement of incompletely spliced viral RNA from the nucleus (Fornerod et al., 1997; Stade et
al., 1997; Bogerd et al., 1995; Stutz et al., 1995). Discrete
functional domains within Rev that mediate its interaction
with cellular proteins and viral RNA are required for nuclear localization, RNA binding, multimerization, and nuclear export. EIAV Rev is a 165 amino acid protein functionally homologous to HIV-1 Rev (Fridell et al., 1993).
The major exon encodes for the nuclear export signal of
EIAV Rev, amino acids 2–25 (Fridell et al., 1993) and was
previously shown to be able to substitute for the HIV-1
or visna virus effector domains (Fridell et al., 1993; Mancuso et al., 1994). A putative nuclear localization signal
was previously mapped to the arginine-rich C-terminus of
EIAV Rev (Harris et al., 1998).
Rev is absolutely required for expression of viral structural genes and production of new virus. Therefore, factors which modulate Rev activity and, consequently, alter
levels of viral gene expression may be important in regulating virus replication in vivo. Rev-attenuated phenotypes
were previously identified during asymptomatic stages of
HIV-1 infection, suggesting that variation in Rev could alter virus replication levels in vivo and contribute to the
clinical outcome of infection (Iversen et al., 1995; Hua
et al., 1996). We previously identified extensive nucleotide substitutions in the second exon of EIAV rev in virus
obtained from an experimentally infected horse (Alexan-
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dersen and Carpenter, 1991). The coexistence of putative
Rev-competent and Rev-deficient phenotypes suggested
that variation in Rev may contribute to virus persistence
through regulation of virus replication. Subsequent in vitro analysis indicated that limited amino acid variation
in Rev could alter Rev-mediated nuclear export activity
(Belshan et al., 1998), further suggesting that variation in
Rev may modulate virus replication during disease.
In the present study, we undertook extensive genetic
and biological analyses of Rev quasispecies during longterm persistence in a single experimentally infected pony.
Consistent with previous studies (Leroux et al., 1997),
novel rev variants were detected throughout infection. Significantly, changes in the genotype and phenotype of Rev
quasispecies correlated with changes in clinical stages of
EIAV infection. These findings indicate that genetic and
biological changes in Rev contributed to the selection of
EIAV variants in vivo, and may be important factors in lentivirus persistence and pathogenesis.
Results
Clinical profile of EIAVWyo-infected pony 524
To accurately reflect the genetic diversity of an in vivo
infection, pony 524 was inoculated with the highly virulent Wyoming strain of EIAV (EIAVWyo), which has been
maintained by serial in vivo passage (Oaks et al., 1998).
This inoculum represents a heterogeneous population
of virus, similar to a natural infection. After inoculation,
pony 524 experienced a clinical disease course characterized by recurring fever cycles interspersed with afebrile
periods ranging from days to months (Figure 1A). The initial acute episode included a biphasic febrile response
and thrombocytopenia from 10 to 22 days postinfection
(DPI). The pony was then afebrile until 39 DPI. Thereafter, pony 524 underwent a period of seven recurrent fever
episodes, which ranged from 2 to 6 days in length. The
last fever episode ended after Day 135, and pony 524 remained afebrile except for two late fever episodes at Days
565 and 799. Febrile episodes were defined as rectal temperature greater than or equal to 101°F. Thrombocytopenia (platelet count less than 105 platelets/ml) was also observed concurrent with the initial fever cycles. After the
initial fever cycles subsided, pony 524 remained persistently thrombocytopenic throughout the experiment. Except for the fever and thrombocytopenia, no other clinical
signs were observed.
Semiquantitative RT-PCR was used to monitor virus
levels at various DPI (Figure 1B). Consistent with previous reports, high virus loads were found in the initial fever period at 12 DPI but fell to a nearly undetectable level
during the afebrile interval at 35 DPI. The highest virus
load, 9.08 × 107 copies RNA/ml, was detected during the
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bounded to 1.38 × 105 copies/ml at 800 DPI. Virus neutralization assays to EIAVWSU-5, a cell-culture-derived
strain of EIAVWyo (O’Rourke et al., 1988), indicated that
broadly reacting neutralizing antibodies appeared after
the chronic fever cycles subsided (201 DPI) (Figure 1C).
Pony 524 maintained elevated neutralizing antibody to
EIAVWSU-5 throughout the remainder of the experiment.
Quasispecies distribution of the inoculum and statistical
analysis of sampling procedure
A potential problem with current methods used to
characterize viral variants is the possible selection of a
subpopulation of variants that may not be reflective of the
population present in vivo. To confirm that the selected
primer pairs did not bias the distribution of observed variants, statistical analyses were performed on the distribution of variants obtained by RT-PCR amplification of the
inoculum. Sequences were amplified using four different
sets of primer pairs (Table 1), designed from conserved
regions flanking exon 2 of rev. Chi-square analyses indicated that the frequency of observed variants in the inoculum was not systematically biased during PCR amplification (not shown). Thus, the observed quasispecies
population is likely to be reflective of variant frequencies
in vivo.
A total of 61 individual clones, at least 10 from each
primer pair, were sequenced from the EIAVWyo inoculum. At the nucleotide level, 39 different genotypes were
detected and translated into both the Rev and the gp45
ORFs. A total of 25 different Rev amino acid variants, designated R1 through R25, were observed in the Rev ORF
(Figure 2). Five genotypes were observed at a frequency
greater than 1, and two clones, R1 and R2, accounted
for 30 and 25% of the sample population, respectively.
Translation in the gp45 ORF identified 30 different variants, designated E1–E30 (Figure 2). The increased number
of variants in gp45 as compared to Rev was primarily the
result of an R to Q change at position 129 of gp45, which
TABLE 1. Primer Pairs Used for Amplification of EIAV Rev
Sequences
Figure 1. Clinical and serological profile of pony 524. (A) Clinical profile
of EIAVWyo-infected pony 524, including platelet counts (gray line, primary y-axis) and fever episodes (columns, secondary y-axis). Fever was
defined as rectal temperature greater than or equal to 101°F. (B) Virus
load, as measured by copies of RNA/ml serum, was determined by semiquantitative RT-PCR for the days indicated by open circles. (C) Virus neutralizing (VN) antibody titer of pony 524 to EIAVWSU-5. VN titers were determined as described under Materials and Methods from serum samples
obtained at 0, 11, 35, 67, 89, 118, 201, 289, 498, 754, and 800 DPI.

Primer
pair
1
2
3
4

recurrent febrile period at 67 DPI. Levels of plasma viral
RNA decreased somewhat in the subclinical period and
were barely detectable at 754 DPI. However, virus re-

Primer
namea
EM 7066
EM 7674C
EM 7066
EM 7680CRI
EM 7160
EM 7674C
EM 7160
EM 7680CR1

Primer sequence (5′–3′)
CAATTTGGCACAATCCATGA
GCGAGAGTTCCTTCTTGGGC
CAATTTGGCACAATCCATGA
GGAATTCCGAGAGTTCCTTCTTGG
GGATTGGGAGCTTCCATTAT
GCGAGAGTTCCTTCTTGGGC
GGATTGGGAGCTTCCATTAT
GGAATTCCGAGAGTTCCTTCTTGG

a C indicates the primer is on the complementary (antisense) strand, and
R1 indicates the presence of an EcoRI restriction site (underlined) at the
3′ end.
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Figure 2. Frequency and distribution of Rev and gp45 sequences in EIAVWyo inoculum. rev/gp45 was amplified from the inoculum and 61 clones were
sequenced and translated into the Rev and gp45 open reading frames. The variant identity (V) and the number of clones of each variant (N) are given
for each reading frame. The sequence of the dominant variant (R1 or EI) is given, and the changes in amino acid sequence in all other variants are
shown. ( · ) Indicates an identical aa to R1 or EI at that position and ( – ) indicates a –1 frameshift mutation.

was a silent change in the Rev ORF. Eight gp45 genotypes
were observed more than once, and the predominant variant, E1, accounted for 16% (10/ 61) of the population.
Genetic changes in rev/gp45
To analyze variation throughout infection, RNA was isolated from the inoculum and from sera samples collected
at various stages of clinical disease, including: acute febrile (12 DPI), first afebrile interval (35 DPI), recurrent febrile (67, 89, and 118 DPI), afebrile (201, 289, 385, and
437 DPI), and late febrile (754 and 800 DPI) periods. The
rev exon 2/gp45 overlapping region of EIAV was amplified using primer pairs 2 and (Table 1), and 22 to 26 in-

dividual clones were sequenced at each time point. Sequences from each time point represent data from two
independent RT-PCR reactions. Novel variants were detected at each time point, and the greatest number of new
variants was observed at 67, 89, 118, and 201 DPI, corresponding to the recurrent fever period and the first sample
of the afebrile period (Table 2).
The amplified region contains overlapping reading
frames for two viral proteins, and we used a variety of genetic analyses to evaluate the potential significance of
genetic changes in each reading frame. Consistent with
observations of other retroviruses (Kim et al., 1996), we
observed a high ratio of transition (Ts) to transversion (Tv)
at each time point. There was also a high ratio of nonsyn-
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Table 2. Genetic Analysis of Variation in rev and gp45 ORFs
Days postinoculation (DPI)
		

Inoc.

12

35

67

89

118

201

289

385

437

754

800

Total

Total clonesa

61

24

23

23

24

24

25

22

26

23

24

23

322

NTb

Variantsc
New variantsd

39
39

13
10

12
7

14
9

20
17

15
12

20
15

9
4

15
10

12
6

11
7

13
9

145

Revb

Variantsc

New variantsd
N/Se

25
25
1.0

7
6
0.9

11
7
7

13
9
2.2

18
14
2.6

11
8
1.9

16
12
2.4

8
3
1.8

12
7
2.1

6
1
1.5

7
5
2.0

8
4
1.2

101

Variantsc
New variantsd
N/Se

30
30
2.3

7
5
1.2

10
4
2.2

14
11
4.0

16
12
1.8

11
7
1.9

15
10
4.2

8
2
3.2

10
4
2.1

12
6
14

8
5
3.4

11
9
7.7

105

gp45b

a Number of clones sequenced at each time point.
b Analysis of variation in nucleotide sequence (NT) or amino acid sequence in the Rev or gp45 open reading frame.
c Number of distinct genotypes present at each time point.
d Number of new genotypes not previously observed.
e Ratio of nonsynonymous to synonymous mutations in that ORF.

onymous (N) to synonymous (S) mutations in both ORFs
of the overlapping region (Table 2). At most time points,
the N/S ratio was similar for both reading frames, although
disproportionate values were sometimes observed. At Day
437, for example, there were 15 nt changes in all the sequences: in the Rev ORF, there was one change in the first
codon position, seven in the second codon position, and
seven in the third codon position. One of the changes in
the third codon occurred concurrent with a second codon change, resulting in six synonymous changes in Rev
and nine nonsynonymous changes, or an N/S of 1.5. In
the gp45 reading frame, the codon positions change with
respect to Rev, resulting in seven changes in the first codon position, seven in the second codon position, and
one in the third codon position, resulting in an N/S ratio
of 14/1 for Env. The overall N/S ratio was greater than 1
for both Rev (1.54) and gp45 (2.15), suggesting that variation in this region was the result of selective pressure.
Application of the Tajima test (Tajima, 1989), which is a
widely used procedure to determine whether nucleotide
variation within a region was the result of either selective
pressure or neutral mutations, confirmed that this region
was indeed under selective pressure. Together, the results
of the genetic analyses indicated a continuing evolution
in Rev and gp45 throughout infection, with changes resulting from selective pressure in both reading frames.
Rev variation throughout clinical disease
The genetic analyses suggested that variation in Rev
was the result of selection rather than neutral mutations.
We previously showed that genetic variation could alter

Rev activity, and we focused our subsequent analyses on
variation in the Rev ORF. Rev amino acid sequences were
examined from the inoculum (Figure 2) and from each of
the 11 time points following infection (Figure 3). As described above, the inoculum was predominated by two
Rev amino acid variants, R1 and R2, which accounted for
30 and 25% of the sample population, respectively. The
consensus sequence for the inoculum was identical to
the sequence of R1. The genetic variation observed was
not distributed uniformly across Rev, and there were two
main regions of variability. Few changes were observed
in the nuclear export sequence, which was previously
mapped to aa 2–25 (Fridell et al., 1993; Mancuso et al.,
1994). However, amino acid position 25, located at the
C-terminus of the nuclear export signal, was highly variable, with either a consensus serine or a leucine mutation
at that position (S25L). At positions 104–108, there was
a GDYQQ consensus sequence, with DGYQR appearing
in a small number of variants. The C-terminal region of
EIAV rev is highly basic, and a putative nuclear localization signal was previously mapped to this region (Harris et
al., 1998). There were only two changes in the C-terminal
region, and both changes retained or increased the basic
character of this region. Changes in the Rev quasispecies
were examined at varying stages of clinical EIAV.
Acute stage. The consensus sequence of R1 was used
as the standard by which the subsequent sera samples
were compared. During the early period after infection,
there were no changes in the consensus sequence (Figures
3 and 4). The Rev quasispecies found in the initial febrile
episode at 12 DPI was genetically very homogeneous. The
variant R1 remained the predominant variant, accounting
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Figure 3. Alignment of Rev aa sequences obtained from sera of pony 524 at 12, 35, 67, 89, 118, 201, 289, 385, 437, 754, and 800 DPI. The variant identity (V) and number of clones of each variant (N) are given for each time point, as well as the total number of clones sequenced (below the N
column). Dominant variants are highlighted in bold. Sequences are compared to R1, which is listed at the top of each time point. For individual sequences, ( · ) indicates an identical aa to R1 at that position, (*) indicates a premature stop codon in the Rev ORF, and (+) indicates a +1 frameshift.
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Figure 4. Consensus Rev aa sequences at each time point (DPI). The variant identity (V) and sequence, relative to R1, are given for each time point. At
two time points, 89 and 201 DPI, no variant was predominant and the consensus sequence was represented by a minor variant, indicated by (*).

for 75% of the sample population. The remaining six variants had not been observed in the inoculum, and each
differed from R1 by a single amino acid. None of the variants contained changes at aa 25 or in the GDYQQ region
at 104–108. In the intervening afebrile period at 35 DPI,
the quasispecies resembled the inoculum. Both R1 and
R2 variants were detected, and the former was again the
predominant variant. Also, we observed two minor variants which had been present in inoculum (R14, R17), and
genetic variability was detected at position 25 (S or L) and
in the DGYQR motif at aa 104–108.
Recurrent febrile stage. The Rev quasispecies observed
in the recurrent febrile period (67, 89, and 118 DPI) differed markedly from the previous populations, as reflected in the appearance of a new consensus sequence
at each time point sampled (Figure 4). Notably, the variant R1, which predominated both the inoculum and the
samples from 12 and 35 DPI, was not detected in any of
the three samples taken during the recurrent febrile stage.
Variants and/or amino acid changes present as minor
populations in earlier time points grew in frequency to
predominate during the recurrent febrile period. For example, variant R32 was only a minor variant at 35 DPI
but represented 43% of the population at 67 DPI. The
consensus sequence at 67 DPI was identical to that of
R32 and had an alanine at aa 82 as well as the DGYQR
motif in region 104–108. At 89 DPI, R32 had decreased
to 14% of the population, and no variant accounted for
more than 20% of the population at this time point. The
consensus sequence at 89 DPI contained a GGYQR motif and was represented by the variant R12, a minor variant which was also present in the inoculum and 67 DPI.
R53 was present as a minor variant at 89 DPI and grew
to predominate the quasispecies population at 118 DPI.
R53 shared the consensus sequence at 118 DPI, which
contained an R97K substitution and a GGYQR motif in
region 104–108. Throughout the recurrent febrile period,
minor variants were observed which contained amino
acid substitutions in the NES, although none contained
the R2-like S25L. In summary, the recurrent febrile period
was characterized by continual changes in the consensus
sequence, with minor variants growing to predominate at
subsequent time points.

Afebrile stage. The first serum sample analyzed after
the recurrent febrile episodes subsided was obtained at
201 DPI, and no variant accounted for more than 20%
of the population at this time point. Surprisingly, after going undetected throughout the recurrent febrile period,
R1 was observed as a minor variant. Although R2, R17,
and R32 were also present as minor variants, the consensus sequence at 201 DPI was unlike those previously observed. The sequence of R78 was identical to the consensus sequence at 201 DPI and consisted of G80D, R97K,
and Q108R. Position 25 was highly variable, with several
variants containing a proline at that residue. At aa 104–
108, both the GDYQQ and the DGYQR motifs were detected in addition to the consensus sequence containing
GDYQR. After 201 DPI, the frequency of R1 grew to predominate each time point analyzed during the remainder
of the afebrile period (289, 385, and 437 DPI), and the
consensus sequence was identical to that of R1 at each of
these time points. Overall, the identity of the minor variants was not highly variable during the afebrile stage, with
R17, R32, and R33 observed in most of the samples. In
contrast to the continual appearance and growth of minor
variants in the recurrent febrile stage, the afebrile stage
was relatively stable genetically and predominated by R1.
Late febrile stage. Two late fever episodes occurred at
565 and 799 DPI. Analysis of rev variation included samples collected at 754 and 800 DPI. R1 was observed as
a minor variant at 754 DPI but was not detected at 800
DPI. A new variant, R93, arose as the predominant variant and the consensus sequence at 754 and 800 DPI and
differed from R1 by seven amino acids. Changes not observed in previous consensus sequences included L25P,
V75A, and R112H. Other changes from R1 found in the
consensus sequence for 754 and 800 DPI were G80D,
R97K, D105G, and Q108R, which had been part of earlier consensus sequences.
In summary, the dynamics of the Rev quasispecies evolution were reflected by the changes in the consensus sequences during the course of disease (Figure 4). These
changes were exemplified by the disappearance and reappearance of R1, which was identical to the consensus
sequence in the acute fever episode, the first afebrile interval, and most of the afebrile period. The replacement
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Figure 5. Variation in Rev-mediated nuclear export activity correlates with temperature and clinical disease. (A) In vitro biological activity of Rev variants from pony 524. Rev exon 2 variants were inserted into a eukaryotic expression vector and transient transfection assays were performed in 293
cells as described under Materials and Methods. CAT assays were normalized to the activity of R1 and the results are presented as a percentage of activity compared to R1. Error bars denote the standard error of the mean. Variants that differed significantly from the activity of R1 are indicated, with P
values represented by (*) P < 0.05, (**) P < 0.005, and (***) P < 0.00005). (B) The predicted (open circles, dotted line) and experimental (closed circles,
solid line) quasispecies Rev activity at different stages of EIAV. The rectal temperature of pony 524 is indicated by solid bars.

of R1 by novel variants during both the recurrent and late
febrile periods is reflected in changes in the consensus sequence during those clinical stages of EIAV infection. The
finding that changes in rev consensus sequences coincided with changes in the clinical disease suggested differences in selective pressures at sequential stages of disease. Surprisingly, these results suggested that the host
environment in the acute and afebrile stages selected for
similar Rev variants.
Biological activity of Rev quasispecies
Genetic analysis of rev variation suggested differences
in selective pressure at different stages of clinical disease.
Therefore, it was important to determine the biological
activity of Rev variants observed in this study. Because it
was not practical to biologically test each clone, Rev variants which were predominant or representative of consensus sequences at any time point were cloned into a
eukaryotic expression vector containing rev exon 1. The
Rev-mediated nuclear export activity was determined
in transient transfection assays as previously described
(Belshan et al., 1998) and results were normalized to R1
(Figure 5A). R2, which contained the single S25L change
from R1, exhibited a level of activity similar to that of R1.
The variant R26 (R52G), which was detected at 12, 118,
and 754 DPI, was the only variant tested that had significantly lower Rev activity (63%) than did R1. Interestingly,
all other variants assayed showed levels of nuclear export activity that were significantly higher than that of R1
(P < 0.05). These included variants that were identical to

the consensus sequences during the recurrent febrile and
late febrile stages of disease (67, 89, 118, 754, and 800
DPI). The consensus sequences represented by the variants R12, R32, R53, and R93 all exhibited approximately
165% activity relative to that of R1. Other variants tested
from the recurrent febrile stage, R42, R45, and R51, also
had Rev activity approximately 175%. Thus, the recurrent
and late febrile periods were predominated by Rev variants that had significantly higher nuclear export activity
than that of R1, which predominated the acute and afebrile periods. Interestingly, 201 DPI was characterized
by the coexistence of Rev variants with low activity (R1
and R2) and variants which had relatively higher activity
(R71 and R72). Similarly, at 754 DPI, we observed a high
frequency of R26 (63% activity) coexisting with the predominant R93 (153% activity). It is possible that 201 and
754 DPI reflect quasispecies transitions between different
stages of clinical disease.
Rev quasispecies activity correlates with clinical stage of
disease
Our analysis of selected Rev variants indicated that
changes in Rev phenotype were associated with changes
in clinical disease. As our data show, however, rev variants existed as a quasispecies population, and no one
variant can define the phenotype of the quasispecies. To
determine whether the Rev quasispecies activity was statistically correlated with different parameters of clinical
disease, we attempted to approximate the average phenotype for the Rev quasispecies at each time point. The
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Table 3. Experimental and Predicted Quasispecies Rev Activity
Rev variant

R1

R2

R4

R12 R17

R26 R32 R42

R45 R51 R53 R71 R72 R86 R93

100 96 222 169 131 63 176 158 193 180 165 162 154 131 153
Rev activitya
b
Stage
DPI 																

Tested/
totalc

(Exp.)
EQRAd

(Pred.)
PQRAe

12
35

18f
6

0
2

0
0

0
0

0
2

1
0

0
2

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

19/24
12/23

98
117

98
124

Recurrent

67
89
118

0
0
0

0
0
0

0
0
0

1
2
2

2
1
0

0
0
2

10
4
0

1
3
0

1
0
0

0
1
0

0
1
12

0
0
0

0
0
0

0
0
0

0
0
0

15/23
12/24
16/24

169
166
153

170
165
158

Afebrile

201
289
385
437

3
9
11
11

4
4
4
4

0
0
0
0

0
0
0
0

1
2
0
1

0
0
0
0

1
1
1
4

0
0
0
0

0
0
0
0

0
0
0
0

0
0
0
0

2
0
0
0

4
0
0
0

0
0
2
0

0
0
0
0

15/25
16/22
18/26
20/23

129
108
107
116

136
117
108
120

Late febrile

754
800

4
0

0
0

0
0

0
0

0
0

6
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
1

10
16

20/24
17/23

115
152

122
151

Acute

a The nuclear export activity level of each variant tested (Ai ), relative to the activity of R1, which is set at 100.
b The days postinfection from which the variants were isolated.
c The number of clones experimentally tested and the total number of clones at each time point.
d The experimental quasispecies Rev activity calculated for each time point.
e The predicted quasispecies Rev activity calculated for each time point.
f The number of times that variant was detected at that time point (vi ).

variants experimentally tested accounted for at least 50%
of all clones present at each time point. Using the activity of each tested variant and its frequency in the population, we calculated a weighted average to derive an experimental quasispecies Rev activity at each time point
(Table 3). Using the phylogenetic relatedness among the
variants (not shown), the untested Rev variants were each
assigned the same Rev activity as the nearest tested variant, and a predicted quasispecies activity was calculated.
At each time point, the calculated experimental and predicted quasispecies Rev activities were nearly identical,
differing at most by 8% (Table 2). Comparison of quasispecies Rev activity with febrile responses of pony 524
indicated that the quasispecies Rev activity was highest
during the recurrent febrile and late febrile stages of EIA

(Table 3, Figure 5B). These findings further suggested a
correlation between Rev activity and clinical stage of disease. Therefore, Pearson correlation coefficients were calculated to test for correlation between the quasispecies
Rev activity and various clinical parameters, including virus titer, platelet counts, and temperature of the horse (Table 4). No significance was detected in comparisons of
experimental or predicted quasispecies Rev activity and
virus titer (P > 0.15) or platelet count (P > 0.45). Analysis by Pearson correlation coefficients found that the temperature of pony 524 was statistically correlated with the
experimental (P = 0.007) and predicted (P = 0.011) quasispecies Rev activity. In addition, the results of the correlation analyses indicated that phenotypic variation in Rev
was correlated with changes in clinical stages of EIAV dis-

Table 4. Correlation between Quasispecies Rev Activity and Clinical Parameters of EIAV Infection

Clinical parameter

Clinical disease stage

Experimental quasispecies
Rev activity

Predicted quasispecies
Rev activity

0.157a
0.453a
0.007a
0.013b
0.010b

0.195a
0.504a
0.011a
0.014b
0.015b

Virus titer
Platelet count
Temperature
Acute vs. recurrent
Recurrent vs. afebrile

a P values calculated using Pearson correlation coefficients.
b P values using general linear models.
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ease. The experimental and predicted quasispecies Rev
activities in the recurrent febrile stage were significantly
higher than the quasispecies Rev activities in the acute
period (P = 0.013, P = 0.014) and in the afebrile period (P
= 0.010, P = 0.015).
Discussion
Antigenic variation in the surface envelope glycoprotein has long been recognized as an important mechanism of immune evasion and lentivirus persistence. Recent studies suggested that variation in other regions of
the viral genome, including the LTR and regulatory genes,
may also contribute to the clinical disease course (Carpenter et al., 1991; Maury et al., 1997; Leroux et al.,
1997; Belshan et al., 1998; Hua et al., 1996). We and
others have observed a high degree of genetic variation in
the rev exon 2/gp45 region of EIAV (Belshan et al., 1998;
Leroux et al., 1997), and we previously demonstrated that
limited amino acid variation in EIAV Rev alters biological activity (Belshan et al., 1998). It was proposed that attenuation of the Rev phenotype may allow EIAV to persist
through down-regulation of viral gene expression and reduced replication, enabling the virus to evade an effective
immune response (Belshan et al., 1998).
To delineate the significance of rev variation in vivo,
we examined both genetic and biological variation of
Rev in an experimentally infected pony. Genetic variation observed in rev during sequential stages of EIAV infection clearly demonstrated that rev variants exist as a
quasispecies population. Genetic analyses indicated that
the Rev ORF evolved throughout infection and that genetic variation was the result of selective pressure rather
than neutral mutations. The frequency at which new
variants were detected was greatest during clinical periods, concomitant with higher levels of virus replication
at these times. Genetic and phenotypic changes in the
Rev quasispecies coincided with changes in clinical disease. Rev variants which were predominant during the
recurrent febrile period had significantly higher nuclear
export activity than the variants predominant during the
acute or afebrile periods. Statistical analyses found that
quasispecies Rev activity was correlated with temperature of the infected pony but not with virus titer or platelet count. Additionally, the quasispecies Rev activity
in the acute and afebrile stages was significantly lower
than the quasispecies Rev activity in the recurrent febrile
stage of disease. Together, these findings indicate that
variants with high Rev activity have a selective advantage during the recurrent and late febrile stages of EIA infection. Therefore, variation in rev may be a contributing
factor of EIAV disease progression.
The dynamic evolution of Rev quasispecies during sequential stages of clinical EIA is exemplified by changes
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in the frequency of R1. This variant, and the closely related R2, clearly represented the predominant genotype
and phenotype in the inoculum and the early time period
following infection. During the subsequent recurrent febrile period, R1 was replaced by a series of closely related Rev variants with significantly higher biological
activity. Surprisingly, R1 reappeared at 201 DPI and predominated during the prolonged afebrile period. Yet, R1
was replaced by the more biologically active R93 during the late febrile period. These genetic changes in the
Rev quasispecies were also reflected in the phenotypic
changes in the quasispecies Rev activity, which was highest during the recurrent febrile and late febrile stages of
disease. In total, these findings indicate that there were
changes in selective pressure at sequential stages of clinical disease. Specifically, our results suggest that changes
in the host environment occurred during the recurrent febrile period and, further, that these changes selected for
variants with significantly higher Rev activity. At present,
the selective pressures present during the recurrent febrile
period are not yet known. Increased Rev activity did not
correlate with virus titer, as might be expected if the selective advantage was solely dependent on the virus replication rate. It is possible that a Rev-specific host immune
response selects for different Rev variants; however, immune evasion does not explain the significant differences
in the biological activity of selected Rev variants. Ongoing studies to identify factors important in selection of Rev
variants may increase our understanding of mechanisms
of EIAV pathogenesis.
Viremia has long been associated with clinical episodes in EIAV-infected animals (Issel and Coggins, 1979).
The abrogation of recurrent clinical episodes is typically
coincident with the maturation of the host immune response and decline in virus replication (Hammond et al.,
1997). The appearance of broadly acting neutralizing antibody in pony 524 at 201–289 DPI was associated with
the resolution of the recurrent febrile period, although virus load remained high through most of the afebrile period. Our model predicted that Rev variant that predominated during febrile periods would differ phenotypically
from variants predominant during afebrile periods. Indeed,
the quasispecies Rev activity was significantly higher in
the recurrent febrile period than in the afebrile period.
However, our model did not predict that quasispecies activity in the acute period would differ significantly from
that in the recurrent febrile period, nor that the acute and
afebrile periods would be so genetically and phenotypically similar. The predominance of R1 during the acute
period indicates that R1 is a robust phenotype, capable of supporting high levels of virus replication. In fact,
the predominance of R1 throughout the afebrile period
was associated with relatively high levels of viremia and
thrombocytopenia that persisted until late in the afebrile
stage of disease (754 DPI). If pony 524 had resolved to a
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clinically inapparent state, in which virus load decreased
to nearly undetectable levels and platelet counts returned
to normal levels, it is possible that the quasispecies Rev
activity would have been statistically correlated with virus load, or that Rev variants less active than R1 would
have been predominant during the afebrile period. In support of this, the least-active variant, R26, comprised 25%
of the observed population at 754 DPI, where virus loads
were barely above the threshold of detection and platelet
counts were near normal levels.
The second exon of Rev is completely overlapped by
a portion of the cytoplasmic tail of the EIAV transmembrane protein gp45. Thus, nucleotide substitutions in this
region may alter Rev and/or gp45. Because of the constraints of maintaining functional proteins in both reading
frames, it might be expected that variation in this region
would be biologically significant. However, it is not immediately obvious which reading frame determines selective advantage. Previous studies of variation in rev/ gp41
of HIV-1 suggested that both genes evolved independently
and that the changes were the result of selection in only
one ORF (Martins et al., 1991). Our data would argue that
EIAV rev/gp45 evolved as a result of selective pressures
in both reading frames. The overall complexity (number
of aa variants at each time point) of Rev and gp45 was
approximately the same throughout infection, and out of
146 nt variants, there was a similar number of total Rev
and gp45 aa variants (101 and 105, respectively). This
suggests that changes in gp45 also contribute to the selective advantage of the observed rev/gp45 variants. The cytoplasmic tail of TM plays important and varied roles in
lentivirus replication, and studies are ongoing to characterize the effect of gp45 variation on EIAV replication. It
is probable that variation in both ORFs contribute to virus
pathogenicity in vivo.
The underlying assumptions of the RT-PCR method are
that all viral quasispecies are amplified with equal efficiency and that the resulting proportions are representative of the starting population. Although these assumptions
have generally been accepted, some reports suggest that
PCR amplification might result in selective amplification
of individual templates, especially in reactions containing
a heterogeneous population of templates (Polz and Cavanaugh, 1998; Suzuki and Giovannoni, 1999; Barnard et
al., 1998; Suzuki et al., 1998). Previous studies suggested
that interactions between primers and templates might alter the efficiency of template amplification and, thus, alter the sample population (Barnard et al., 1998; He et al.,
1994; Suzuki and Giovannoni, 1999), or that primer pairs
may systematically bias PCR amplification (Suzuki and
Giovannoni, 1999; Polz and Cavanaugh, 1998; Barnard
et al., 1998). However, these studies have generally involved two or three different templates of known concentrations. The complex nature of viral quasispecies in vivo
can further complicate sequencing studies. Our statistical
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analyses of primer-pair bias in the inoculum indicated that
the frequency of observed variants was not systematically
biased during PCR amplification, so the random samples
were likely reflective of variant frequencies in vivo. The
risk of bias may have been reduced by designing primers to conserved target sequences and using primers with
similar GC content and optimal annealing temperatures.
Taken together, our results suggest that randomly sampled
viral populations obtained by RT-PCR can reflect in vivo
populations. This offers confidence in the characterization of viral quasispecies present in vivo and strengthens
interpretations of studies examining the role of virus variation in immune evasion and disease progression.
Most studies of EIAV persistence in vivo used a cloned,
cell-culture-propagated virus as an inoculum and were
limited to analysis of febrile periods. Inocula comprised
of a homogenous population of virus have been useful in
identifying genetic changes that arise during an in vivo infection. In this study, our intention was to better reflect a
naturally occurring infection in an experimentally infected
animal. Therefore, the inoculum used was obtained from
a donor pony undergoing its first fever episode and represented a heterogeneous population of virus rather than a
single clonal population. Although this method required
a more extensive analysis, we believe it provided an accurate representation of the complex nature of EIAV evolution throughout disease within a single infected pony.
The heterogeneous nature of the inoculum, in combination with the extensive sampling and genetic analysis at
sequential time points, allowed us to examine the genetic
variants that made up the rev quasispecies and the biological phenotype of the Rev quasispecies that were selected at variable stages of clinical disease. It is clear that
genetic and phenotypic changes in the Rev quasispecies
were associated with changes in clinical stages of disease
in this pony. While analysis of additional EIAV-infected
ponies is needed to fully elucidate the biological significance of Rev variation, the findings presented here indicate that variation in virus regulatory proteins can contribute to lentivirus persistence.
Materials and Methods
Experimental infection
The experimental infection of pony 524 was previously
reported (Oaks et al., 1998). The pony was infected intravenously with 103 horse infectious doses of the highly
virulent Wyoming strain of EIAV (EIAVWyo). Physical examinations, rectal temperatures, hemograms, and platelet
counts were performed daily during clinical episodes and
intermittently during chronic clinical disease or subclinical infection. Sera and plasma were collected, processed,
and stored at –80°C until analyzed.
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Virus neutralization assay
Assays were performed using equine dermal (ED)
cells maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 20% fetal bovine serum, penicillin, and streptomycin as previously described (Carpenter et al., 1987). ED cells were seeded 1 day prior to infection at 105 cells/well in a six-well dish. Serum from pony
524 was heat-inactivated at 60°C, to destroy complement,
and was serially diluted twofold in supplemented media.
Five hundred focus-forming units of EIAVWSU-5, a cell culture-derived strain of EIAVWyo (O’Rourke et al., 1988), in
a 100-μl volume was incubated with 100 μl of serially diluted pony 524 serum at 37°C for 1 h. Duplicate wells of
ED cells were inoculated with 100 μl of virus–serum mixture in the presence of 8 μg/ml polybrene, and the media
was changed the following day. Cells were incubated for
an additional 72 h and fixed with 100% methanol, and
immunocytochemistry was performed using convalescent
anti-EIAV horse sera to detect foci of virus-infected cells
(Carpenter et al., 1987). Results are expressed as the serum neutralization titer, defined as the reciprocal of the
highest serum dilution that gave an 80% reduction in foci
as compared with that of preimmune and negative control serum.
Amplification and sequence analysis of viral variants
EIAVWyo inoculum was obtained as a serum sample
collected from an experimentally infected foal experiencing its initial fever episode at 7 days postinfection (DPI).
To obtain viral RNA, 100 μl of EIAVWyo inoculum or pony
524 serum was pelleted by centrifugation at 93,000g for
1 h at 4°C. Viral RNA was isolated from these pellets by
guanidine thiocyanate lysis and acid phenol–chloroform
extraction using a commercially available kit (Ambion,
Austin, TX) and resuspended in 24 μl RNase-free glass-distilled water containing 0.1 mM EDTA. RNA samples were
DNase I treated using the methods of Huang et al. (1996).
Briefly, two units of DNase I (Ambion) were added to 3 μl
of viral RNA, 20 mM MgCl2, 1 mM of each dNTP, 1× PCR
buffer II (Perkin–Elmer, Branchburg, NJ), 20 units of RNase
inhibitor, and 2.5 μM of random hexamers in a total volume of 20 μl. The reaction was incubated at 37°C for 30
min and heated to 75°C for 5 min to inactivate the DNase I. After cooling to 4°C, 50 units of Moloney murine
leukemia virus reverse transcriptase were added. Reactions were incubated at 42°C for 45 min, heated to 99°C
for 5 min to inactivate the reverse transcriptase, and then
cooled to 5°C for 5 min. The reaction was brought up to
100 μl in 1× PCR buffer II with 2 mM MgCl2, 0.2 μM of
each dNTP, 2.5 units Taq polymerase (Perkin–Elmer), and
1 μM of each primer.
Primers were designed based on conserved regions
flanking the second exon of rev (Table 1). PCR amplification conditions consisted of 37 cycles of denaturation at
94°C for 2 min, annealing at 50°C for 1 min, and exten-
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sion at 72°C for 1 min. The initial and final cycles contained a prolonged extension at 72°C for 5 min. A 2-μl
aliquot of PCR product was TA-cloned into pGEM-T vectors as recommended by the manufacturer (Promega,
Madison, WI) and transformed into Escherichia coli DH5. Positive clones were identified by colony blot hybridization using a subgenomic fragment of rev labeled with
[32P]dTTP by random-primed labeling (Roche Molecular Biochemicals, Indianapolis, IN). Plasmids were isolated from positive clones using a commercially available
kit, Wizard Plus Miniprep (Promega), and the rev inserts
were sequenced bidirectionally with vector primers flanking the insert. All sequencing was performed by the Iowa
State University DNA Synthesis and Sequencing Facility using an automated DNA sequencer. Sequences were
aligned by MacVector and AssemblyLIGN software (Oxford Molecular, Beaverton, OR). To estimate the RT-PCR
error rate, viral mRNA was isolated from a clonal cell line
stably transfected with an EIAV proviral DNA clone, reverse transcribed and amplified with Taq polymerase. The
amplicons were cloned and 17 individual clones were sequenced. The error rate of the RT-PCR amplification procedure was determined to be 0.025%, or three substitutions per 11,991 base pairs sequenced.
Construction of Rev expression vectors
rev variants were subcloned into pERevWT, a Rev expression vector previously described as pcH21 (Belshan
et al., 1998). This plasmid contains Rev cDNA in the
pCR3 background (Invitrogen, Carlsbad, CA). pERevWT
was digested with the restriction endonuclease ApaI to remove rev exon 2. The digested plasmid was gel-purified,
dephosphorylated, and ligated with the exon 2 sequence
variants. Two methods, based on the direction of the inserts in pGEM-T, were employed to move variant exon 2
sequences into the pERevWT background. Inserts in the
“forward” direction were digested with ApaI, gel-purified, and ligated into the digested pcRevWT background.
Inserts in the “reverse” orientation were PCR-amplified
with the EM7160 primer and a 3′ EIAV primer containing an ApaI site (underlined): 5′-CTGGGCCCTCATAAATGTTTCCTCCTTCGC. The PCR products were purified,
digested with ApaI, and ligated into the pcRevWT background. All clones were verified for directionality by restriction mapping and confirmed by sequencing.
Statistical analyses
A two-dimensional chi-square test was used to test
the null hypothesis that the frequency distribution of observed variants and the choice of primer pairs was independent. The chi-square statistic was calculated, and
the P value was determined for each contingency table.
The statistical threshold used in this study was 95% confidence. Subset pairwise analyses were also performed
on the data, and the results were interpreted with Bon-
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ferroni’s correction (Miller, 1981). For the Monte Carlo
simulation (Rubinstein, 1981) comparing the four primer
pairs, the chi-square distance was calculated between
the four sets of simulated data. The data were simulated
10,000 times, and experimentally observed chi-square
distances were compared with the 10,000 simulated distances to find the percentile ranking, which correlates to
the P value. For the pairwise analyses of primer pairs,
10 variants were randomly created for each set of the
two simulated primer pairs. The remainder of the simulation was the same as just described, except the Kullback distance (Bishop et al., 1975) was calculated rather
than chi-square distance.
The transition to transversion ratio and the nonsynonymous-to-synonymous mutation ratio were calculated using the program SITES, version 1.1 (Hey and Wakeley,
1997). The Tajima test (Tajima, 1989), which determines
whether nucleotide variation within a region was the result of selective pressure or neutral mutations, was also
performed using SITES.
The experimental quasispecies Rev activity (QRA) for
each time point was calculated as the average Rev activity of tested variants, weighted by frequency of the tested
variants, using the following equation:
[insert equation]
where n is the number of different variants tested, vi is
the number of times variant i was detected at that time
point, and Ai is the Rev activity level for variant i. A phylogenetic tree was constructed, and untested variants
were assigned the same activity as the nearest tested
variant in the tree. These values were used to estimate
the predicted quasispecies Rev activity in a manner similar to the calculation of the experimentally Rev quasispecies activity. The statistical package SAS, version 6.03
(SAS Institute, 1988), was used to examine possible correlation between the experimental and predicted quasispecies Rev activity and different parameters of clinical
disease. Pearson correlation was used to test virus titer,
platelet counts, and temperature of the infected pony.
A quadratic model was used to fit the relationship between quasispecies Rev activity and temperature, and
analysis of the studentized residuals was used to test the
quadratic model. Comparison of quasispecies Rev activity between different stages of disease was done using a
general linear models procedure, adjusted for multiple
comparisons by Tukey–Kramer correction.
Quantification of virus load
RNA quantification standards were synthesized by in
vitro transcription from a linearized plasmid containing a
450-base pair fragment of EIAV gag (pEIAp26.1). The RNA
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was purified by extraction with Trizol reagent, treated
with 6 U of DNase I (Ambion) for 45 min at 37°C to remove plasmid DNA, and then extracted again with Trizol
reagent. Final RNA preparation was quantified by spectrophotometry, aliquoted, and stored at –80°C. The absence
of contaminating plasmid DNA was verified by PCR without reverse transcription.
To create standards, known copy numbers of RNA
standards were assayed in triplicate as described below;
these included 2 × 107, 2 × 106, 2 × 105, 2 × 104, and
2 × 103 copies of RNA. Reaction products were visualized in ethidium bromide-stained agarose gels, and their
densities quantified using a commercial digital imaging
system (IS1000; Alpha Innotech, San Leandro, CA). The
mean density for each copy number was plotted against
the log10 of the copy numbers to construct a standard
curve.
The one-tube, semiquantitative RT-PCR protocol was
modified from that described by Hamel et al. (1995). The
reaction buffer contained 50 mM KCl, 10 mM Tris (pH
9.0), 0.1% Triton X-100, and 2.0 mM MgCl2, and each
reaction contained 0.4 mM deoxyribonucleotide mix
(Roche Molecular Biochemicals), 1 U of RNase inhibitor (Roche Molecular Biochemicals), 20 U of Moloney
murine leukemia virus reverse transcriptase (SuperScript
II; Gibco BRL, Rockville, MD), 1.5 U of Taq DNA polymerase (Gibco BRL), and 90 pmol of the forward primer
(5′- ACTACTTGGGTGAATACCAT) and 90 pmol of the reverse primer (5′-TCTGCCTAAACTGATCAAAA) in a final
volume of 25 μl. These oligonucleotides prime both reverse transcription as well as the subsequent PCR reaction, and amplify a 322-base pair segment of the EIAV
capsid protein gene (p26) (nts 897–1199). Amplification
was performed as follows: 42°C for 40 min, DNase I inactivation at 95°C for 3 min, and 40 cycles of 94°C for 30
s, 58°C for 30 s, and 72°C for 30 s. Each RT-PCR run included positive and negative controls. Complete removal
of all DNA from samples was confirmed by performing a
duplicate reaction without reverse transcriptase. Following amplification, 13 μl of the PCR reaction was analyzed
by electrophoresis through 2.0% agarose and visualized
by ethidium bromide staining and ultraviolet light. Serum
samples from each time point were assayed in duplicate,
and their mean density values were used to calculate copy
numbers of viral RNA from the standard curve. RT-PCR reactions for standards and samples were performed simultaneously using a reagent–master mix, and were analyzed
simultaneously in a single agarose gel.
CAT assays
293 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum and penicillin/streptomycin. Transient transfections
and CAT assays were performed using 293 cells as previ-
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ously described (Belshan et al., 1998). Briefly, 1 μg of either pcDNA3 or Rev variant plasmid was transfected by
calcium phosphate coprecipitation with 0.2 μg of pERREAll reporter plasmid, 0.2 μg of pCH110 (Amersham Pharmacia Biotech, Piscataway, NJ), and 0.6 μg of pUC19.
pERRE-All, a derivative of pDM138 containing EIAV nts
5280–7534, was described previously (Belshan et al.,
1998). Each experiment also included a sham group,
which contained no reporter plasmid, but an additional
0.2 μg of pUC19. Two days posttransfection, cells were
harvested, resuspended in 0.3 ml 0.25 M Tris (pH 7.5),
lysed by freeze/thawing, and assayed for β-galactosidase
activity, to normalize CAT assays for transfection efficiency. Normalized lysates were assayed for CAT activity
in a 0.1 ml volume with 3 μl [14C]chloramphenicol and 1
mM acetyl CoA. Acetylated products were separated by
thin-layer chromatography and the percentage of acetylation was determined by quantification by phosphorimager. Experiments were performed in triplicate and results
summarize a minimum of nine independent transfections. Statistical significance was determined by analysis
of variance.
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